

NOVO NORDISK A S  
Form IRANNOTICE  
February 09, 2017

U.S. Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

February 9, 2017

**Re: Notice of disclosure filed in Exchange Act Annual Report under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act**

Dear Sirs,

Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby provided that Novo Nordisk A/S has made disclosure pursuant to those provisions in its Annual Report on Form 20-F for the year ended December 31, 2016, which was filed with the Securities and Exchange Commission on February 9, 2017.

Sincerely,

/s/ Lars Fruergaard Jørgensen

Lars Fruergaard Jørgensen  
President and Chief Executive Officer

/s/ Jesper Brandgaard

Jesper Brandgaard  
Executive Vice  
President and  
Chief Financial  
Officer

Novo Nordisk A/S Novo Allé Telephone: Internet:  
DK-2880 Bagsværd +45 4444 8888 novonordisk.com  
Denmark

Telefax: CVR Number:  
+45 4444 6626 24256790